Travoprost (Synonyms: AL-6221, Flu-Ipr, 16mtrifluoromethylphenoxy tetranor PGF2α isopropyl ester, Travoprost) |
Catalog No.GC37822
One-Click Copy Product Info
|
Travoprost is a synthetic ester prodrug of a prostaglandin F2α analogue that inhibits IKir6.2/Sur2a ion channel with an IC50 value of 3μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 157283-68-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Travoprost is a synthetic ester prodrug of a prostaglandin F2α analogue that inhibits IKir6.2/Sur2a ion channel with an IC50 value of 3μM [1]. Travoprost is hydrolyzed into the active FP prostaglandin receptor agonist by the cornea and sclera, improving trabecular outflow facility[2].Travoprost has been widely used as an eye drop to reduce intraocular pressure in vivo experiments[3].
In vitro, Travoprost treatment at 20µg/ml for 20min significantly inhibited the viability of primary human limbal epithelial cells (LECs) and inhibited cell proliferation[4]. 35µg/ml Travoprost treatment for 72 hours significantly inhibited CD31 and CD54 expression in conjunctiva-derived epithelial cells[5]. Aniridia limbal stromal cells (AN-LSCs) were treated with 0.313μg/ml Travoprost for 20 minutes, resulting in an increase in the MMP-9 protein level of the cells, and an elevation in the mRNA levels of PTGFR and JNK[6].
References:
[1] Friesacher T, Houtman M J C, Chen X, et al. Development of IKatp ion channel blockers targeting sulfonylurea resitant mutant KIR6. 2 based channels for treating DEND syndrome[J]. Biophysical Journal, 2022, 121(3): 388a.
[2] Toris C B, Zhan G, Fan S, et al. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure[J]. Journal of glaucoma, 2007, 16(2): 189-195.
[3] Lim K S, Nau C B, O'Byrne M M, et al. Mechanism of action of Bimatoprost, Latanoprost, and Travoprost in healthy subjects: a crossover study[J]. Ophthalmology, 2008, 115(5): 790-795. e4.
[4] Li S, Stachon T, Liu S, et al. The effect of travoprost on primary human limbal epithelial cells and the siRNA-based aniridia limbal epithelial cell model, in vitro[J]. Plos one, 2025, 20(8): e0330492.
[5] Guenoun J M, Baudouin C, Rat P, et al. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells[J]. Investigative ophthalmology & visual science, 2005, 46(7): 2444-2450.
[6] Li S, Stachon T, Liu S, et al. Increased sensitivity of primary aniridia limbal stromal cells to travoprost, leading to elevated migration and MMP-9 protein levels, in vitro[J]. PloS one, 2025, 20(6): e0326967.
| Cell experiment [1]: | |
Cell lines | Human limbal epithelial cells (LECs) |
Preparation Method | Human limbal epithelial cells (LECs) were seeded into individual wells of six-well culture plates, and 2.5ml of KGM3 medium was added to each well. After the cells reached complete confluence, the cells were digested using trypsin-EDTA and subsequently reseeded into 96-well plates. LECs were cultured at 37°C, 95% humidity, and 5% CO2 under standard culture conditions. The cells were treated with various concentrations of Travoprost (0.078, 0.156, 0.313, 0.625, 1.25, 2.5, 5, 10, 20, 40μg/ml) for 20min and analyzed for viability. |
Reaction Conditions | 0.078, 0.156, 0.313, 0.625, 1.25, 2.5, 5, 10, 20, 40μg/ml; 20min |
Applications | Travoprost treatment decreased the cell viability of LECs in a dose-dependent manner. |
References: | |
| Cas No. | 157283-68-6 | SDF | |
| Synonyms | AL-6221, Flu-Ipr, 16mtrifluoromethylphenoxy tetranor PGF2α isopropyl ester, Travoprost | ||
| Canonical SMILES | O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)COC2=CC=CC(C(F)(F)F)=C2)[C@H](O)C[C@@H]1O | ||
| Formula | C26H35F3O6 | M.Wt | 500.55 |
| Solubility | Ethanol: 60 mg/mL (119.87 mM); DMSO: ≥ 41.67 mg/mL (83.25 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9978 mL | 9.989 mL | 19.978 mL |
| 5 mM | 399.6 μL | 1.9978 mL | 3.9956 mL |
| 10 mM | 199.8 μL | 998.9 μL | 1.9978 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: An oil
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)